Frozen, Non-UK Derived Pathogen Reduced Plasma.

Descriptions

NHSBT requires pathogen reduced plasma which will then be subsequently manufactured into FFP, Single and pooled cryoprecipitate for paediatric and neonatal use, for recipients born on/after 1.1.1996. Those recipients are deemed not to have been exposed to the risk of vCJD in the UK food chain. Plasma must be sourced from a country outside the UK with vCJD prevalence >2.5 log lower than the UK. The TPSG approved the following countries for supply of plasma based on SaBTO 2013: Australia, Austria, Canada, Finland, New Zealand, Norway, Poland, Sweden and the US. For other transfusion transmitted infections the final component risk must be ‘no worse than current’ (detailed in the component specification).The contract shall commence the date the contract is signed. The Term of the contract expires 2 years from the end of the Set Up Period. The Contract consists of a option to extend for 2 periods of 12 months. The Maximum Term of the Contract is 4 years from the end of the Set Up Period.